141.18% 0.024

Galera Therapeutics Inc (GRTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché GRTX Giù? Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Galera Therapeutics Inc Stock (GRTX) Company Profile

Galera Therapeutics Inc

Healthcare (1118)

Biotechnology (624)

Prossima data di guadagno

Ultimi documenti SEC

GRTX's Discussions on Twitter

Compare GRTX vs VRTX, REGN, ARGX, ALNY, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GRTX Galera Therapeutics Inc	0.041	0	0	149.05M	-6.05M	1.9846
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-08-10	Downgrade	Piper Sandler	Overweight → Neutral
2021-10-19	Downgrade	BTIG Research	Buy → Neutral
2021-10-19	Downgrade	BofA Securities	Buy → Underperform
2021-04-26	Ripresa	Credit Suisse	Outperform
2020-12-16	Aggiornamento	Credit Suisse	Neutral → Outperform
2020-12-07	Iniziato	H.C. Wainwright	Buy
2019-12-02	Iniziato	BTIG Research	Buy
2019-12-02	Iniziato	BofA/Merrill	Buy
2019-12-02	Iniziato	Citigroup	Buy
2019-12-02	Iniziato	Credit Suisse	Neutral

Mostra tutto

Galera Therapeutics Inc Borsa (GRTX) Ultime notizie

Galera Therapeutics Inc Azioni (GRTX) Dati Finanziari

Galera Therapeutics Inc (GRTX)

Galera Therapeutics Inc Stock (GRTX) Company Profile

Compare GRTX vs VRTX, REGN, ARGX, ALNY, INSM

Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades

Galera Therapeutics Inc Borsa (GRTX) Ultime notizie

Galera Therapeutics schedules combined 2025 and 2026 annual meeting for May - Investing.com Australia

Galera Sets Deadlines for 2026 Combined Annual Meeting - TipRanks

Galera Therapeutics schedules combined 2025-2026 annual meeting for May 8, 2026; April 13 proposal deadline - TradingView

Galera Therapeutics (GRTX) sets 2026 meeting date and April 13 proposal deadline - Stock Titan

Galera Therapeutics 10-K: Revenue $0, EPS $0.64 on $149.0M Net Income - TradingView

Galera Therapeutics (GRTX) exits radiotherapy, bets on pan-NOS breast cancer drug - Stock Titan

Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener

GRTX (Galera Therapeutics) NonCurrent Deferred Revenue : $0.00 Mil (As of Sep. 2025) - GuruFocus

Galera Therapeutics Sells Dismutase Mimetics Portfolio to Biossil in $108.5 Million Deal - MSN

GRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Galera Therapeutics Updates Preferred Stock Conversion Provisions - TipRanks

Galera Therapeutics (GRTX) grants board discretion on Series B conversion - Stock Titan

Galera Therapeutics Grants Retention Bonus to Key Officer - TipRanks

Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - BUCKSCO.Today

Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor - marketscreener.com

Galera Therapeutics completes acquisition of Nova Pharmaceuticals - Intellectia AI

Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - MSN

Head to Head Analysis: Lite Strategy (NASDAQ:LITS) and Galera Therapeutics (NASDAQ:GRTX) - Defense World

GRTX (Galera Therapeutics) EV-to-OCF : 0.32 (As of Dec. 19, 2025) - GuruFocus

Chmn Sorensen Sells 70,000 ($1.4K) Of Galera Therapeutics Inc [GRTX] - TradingView

GRTX Form 4: CEO Sorensen reports 70,000-share stock sale - Stock Titan

Chmn Sorensen Files To Sell 70,000 Of Galera Therapeutics Inc [GRTX] - TradingView — Track All Markets

Galera Therapeutics, Inc. SEC 10-Q Report - TradingView

Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener

[10-Q] Galera Therapeutics, Inc. Quarterly Earnings Report | GRTX SEC FilingForm 10-Q - Stock Titan

Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D - Citeline News & Insights

Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo

Canadian company purchases Galera Therapeutics’ dismutase mimetics portfolio - Pennsylvania Business Report -

Galera Therapeutics Sells Assets to Biossil Inc. - TipRanks

Biossil to acquire Galera’s dismutase mimetics portfolio for up to $105M - MSN

Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz

Galera Therapeutics (GRTX) Sells Asset Portfolio to Biossil - GuruFocus

Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance

Malvern firm selling drug portfolio in potential $105M deal after FDA setback - The Business Journals

Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan

Oral Mucositis Market Size & Share | Industry Report, 2033 - Grand View Research

NanoCell Therapeutics Expands Scientific Advisory Board With Global Experts in Gene Therapy and Clinical Development - MyChesCo

Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN) - The Lancet

Legend Biotech CorporationAmerican Depositary Shares (NQ: - FinancialContent

Galera Therapeutics Amends Royalty Agreement with Clarus - The Globe and Mail

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance

Windtree Therapeutics to Launch BNB Crypto Treasury Strategy in Groundbreaking $200 Million Deal - MyChesCo

Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewswire

Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire

Galera Therapeutics Inc. (GRTX) reports earnings - qz.com

Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights

Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech

Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals

Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics - The Globe and Mail

Galera Therapeutics Inc Azioni (GRTX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a GRTX